NCT00041340View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

July 31, 2006

Conditions
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00041340 - Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer | Biotech Hunter | Biotech Hunter